CSIMarket Company Name, Ticker, Customers, else..
 
Editas Medicine Inc   (NASDAQ: EDIT)
 
Price: $3.2300 $0.15 4.870%
Day's High: $3.2300000190734863 Week Perf: 5.56 %
Day's Low: $ 3.04 30 Day Perf: 11.38 %
Volume (M): 1,385,462 52 Wk High: $ 4.54
Volume (M$): $ 0 52 Wk Avg: $2.74
Open: $3.04 52 Wk Low: $1.66



 Market Capitalization (Millions $) 316
 Shares Outstanding (Millions) 98
 Employees 87
 Revenues (TTM) (Millions $) 39
 Net Income (TTM) (Millions $) -109
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 1

Business Description


Editas Medicine Inc is a leading biotechnology company that specializes in developing CRISPR gene editing technology for therapeutic purposes. The company aims to improve patients' lives by treating and potentially curing genetic diseases through precise editing of their DNA. Editas Medicine uses its proprietary genome editing platform to address a wide range of genetic diseases, including rare and inherited conditions. The company focuses on developing innovative therapies and partnering with other organizations to bring these treatments to patients. Editas Medicine is at the forefront of the gene editing field and has the potential to revolutionize medicine by providing targeted and personalized treatments.


   Company Address: 11 Hurley Street Cambridge 2141 MA
   Company Phone Number: 401-9000   Stock Exchange / Ticker: NASDAQ EDIT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRA        6.09% 
BDTX   -4.93%    
IMCR   -1.34%    
IPSC        4.2% 
KRYS        1.93% 
RGNX   -7.45%    
• View Complete Report
   



Product Service News

Advancements in Gene Editing for Sickle Cell Disease and Beta Thalassemia Editas Medicine Reports Promising Results f...

Published Thu, Jun 12 2025 7:58 AM UTC

Editas Medicine, a pioneering company in the field of gene editing, presented significant advancements in their proprietary targeted lipid nanoparticle (LNP) delivery system at the European Hematology Association (EHA) 2025 Congress held in June. The focus of their findings was on the in vivo editing of the HBG1/2 promoter, a critical target for treating sickle cell disease...
Clinical Study

Breakthrough Data on Reni-cel for Sickle Cell Disease Unveiled at ASH Annual Meeting,

Published Mon, Dec 9 2024 5:00 PM UTC

Updated Insights into Reni-cel Therapy for Severe Sickle Cell Disease Presented at ASH Annual Meeting In a recent development at the 64th American Society of Hematology (ASH) Annual Meeting, Editas Medicine unveiled updated clinical data from its RUBY trial, focusing on the investigational gene-edited therapy, Reni-cel, for patients grappling with severe sickle cell disease....
Management Announcement

Editas Medicine: Balancing the Future of Gene Editing with Strategic Financial Maneuvers Amidst Industry Challenges,

Published Tue, Oct 22 2024 11:00 AM UTC

Editas Medicine: Navigating Financial Challenges while Pioneering Gene Editing SolutionsIn an ever-evolving biotechnology landscape, Editas Medicine Inc. is making strides both in clinical advancements and financial strategy. The company recently announced significant progress towards its 2024 goals, revealing pivotal developments in its quest to treat genetic disorders suc...
Financing Agreement

Editas Medicine: A Strategic Leap in Capitalization and Clinical Achievement

Published Thu, Oct 3 2024 10:01 PM UTC

Balancing Financial Strength Amidst Clinical AdvancementsIn the fast-evolving biotechnology landscape, Editas Medicine Inc. has made a significant move that not only fortifies its balance sheet but also sets the stage for promising pipeline development and strategic priorities. The company’s recent announcement of a non-dilutive capital influx exceeding $50 million from DR...
Clinical Study

Editas Medicines Reni-cel Shows Promise in Treating Sickle Cell Disease, Advances in Gene Editing Technology, and Ex...

Published Fri, Jun 14 2024 7:01 AM UTC

In a groundbreaking achievement, Editas Medicine, a leading biotechnology company, presented new safety and efficacy data from the RUBY trial of Reni-cel at the prestigious European Hematology Association (EHA) Annual Congress. The trial included 18 patients with sickle cell disease, and the results have been nothing short of remarkable. All patients treated with Reni-cel re...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 8.17
Price to Sales (Expected) -
Price to Book 71.72
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.11
Working Capital Ratio 3.22
Leverage Ratio (MRQ) 32.88
Total Debt to Equity 12.4
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.23 $
Revenues (TTM) 0.4 $
Cash Flow (TTM) -
Cash 1.26 $
Book Value 0.05 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 444,747
Net Income per Employee (TTM) -1,252,345
Receivable Turnover Ratio (TTM) 5.84
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.21

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -883.19 %
Net Margin (MRQ) -882.44 %
Net Cash Flow Margin (MRQ) -812.33 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Editas Medicine Inc's Segments
Reportable Segment    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.